首页 > 最新文献

Cancer Epidemiology最新文献

英文 中文
Temporal trends in age and stage-specific incidence of colorectal cancer in Saudi Arabia: A registry-based cohort study between 1997 and 2017 沙特阿拉伯结直肠癌年龄和分期发病率的时间趋势:1997年至2017年间基于登记簿的队列研究。
IF 2.4 3区 医学 Q3 ONCOLOGY Pub Date : 2024-11-13 DOI: 10.1016/j.canep.2024.102699
Norah Alsadhan , Mar Pujades-Rodriguez , Sultana A. Alhurishi , Farag Shuweihdi , Cathy Brennan , Robert M. West

Background

In Saudi Arabia, colorectal cancer (CRC) is the most common cancer in men and the third in women, posing a significant health burden. A comprehensive report of CRC incidence rates and trends in Saudi Arabia is lacking. This study aims to examine trends in CRC incidence among the Saudi population.

Methods

We used data from the Saudi Cancer Registry to examine CRC age-specific incidence rates (ASIR) and age-standardized incidence rates (ASR) between 1997 and 2017. Joinpoint regression analysis was used to determine the magnitude and direction of observed trends stratified by age, sex, and CRC stage at diagnosis. Trends were measured using the annual percentage change (APC) and the average annual percentage change (AAPC) in CRC incidence rates.

Results

In total, 19,463 new CRC cases were identified during the study period. Since 1997, ASR for CRC has steadily increased in men and women overall, irrespective of disease stages. The ASIR increased across all age groups and was more pronounced in older patients. Women aged 40–49 had a higher increase in incidence than men (AAPC= 5.3 % vs.4.7 %). Males aged 70–79 had an AAPC of 10.2 %, twice that of females (AAPC= 4.9 %). A consistent rise in ASIR was observed across all CRC stages and age groups in males and females. In recent years, males under 50 had a higher APC for distant CRC than females, while females aged 50–74 experienced a steeper increase in distant CRC than males.

Conclusion

We report a marked increase in the incidence of CRC over time in Saudi Arabia, affecting men and women across all age groups and disease stages at diagnosis. Our findings underscore the need to identify underlying risk factors and to develop and implement effective prevention policies and strategies, including screening programs to facilitate early detection and treatment.
背景:在沙特阿拉伯,结肠直肠癌(CRC)是男性最常见的癌症,是女性的第三大癌症,对健康造成了重大负担。沙特阿拉伯缺乏有关 CRC 发病率和趋势的全面报告。本研究旨在探讨沙特人口中 CRC 发病率的变化趋势:我们利用沙特癌症登记处的数据,研究了 1997 年至 2017 年间 CRC 年龄特异性发病率(ASIR)和年龄标准化发病率(ASR)。联结点回归分析用于确定按年龄、性别和确诊时的 CRC 分期分层的观察趋势的幅度和方向。使用 CRC 发病率的年度百分比变化(APC)和平均年度百分比变化(AAPC)来衡量趋势:研究期间共发现 19,463 例新的 CRC 病例。自 1997 年以来,无论疾病处于哪个阶段,男性和女性的 CRC 发病率总体上都在稳步上升。所有年龄组的ASIR都有所上升,老年患者的ASIR上升更为明显。40-49 岁女性的发病率增幅高于男性(AAPC= 5.3% 对 4.7%)。70-79 岁男性的 AAPC 为 10.2%,是女性的两倍(AAPC= 4.9%)。在所有儿童癌症阶段和年龄组中,男性和女性的 ASIR 均呈持续上升趋势。近年来,50 岁以下男性的远处 CRC APC 比女性高,而 50-74 岁女性的远处 CRC 比男性增加得更快:我们的报告显示,随着时间的推移,沙特阿拉伯的 CRC 发病率明显上升,男性和女性在诊断时均处于不同的年龄段和疾病阶段。我们的研究结果表明,有必要找出潜在的风险因素,并制定和实施有效的预防政策和策略,包括筛查计划,以促进早期发现和治疗。
{"title":"Temporal trends in age and stage-specific incidence of colorectal cancer in Saudi Arabia: A registry-based cohort study between 1997 and 2017","authors":"Norah Alsadhan ,&nbsp;Mar Pujades-Rodriguez ,&nbsp;Sultana A. Alhurishi ,&nbsp;Farag Shuweihdi ,&nbsp;Cathy Brennan ,&nbsp;Robert M. West","doi":"10.1016/j.canep.2024.102699","DOIUrl":"10.1016/j.canep.2024.102699","url":null,"abstract":"<div><h3>Background</h3><div>In Saudi Arabia, colorectal cancer (CRC) is the most common cancer in men and the third in women, posing a significant health burden. A comprehensive report of CRC incidence rates and trends in Saudi Arabia is lacking. This study aims to examine trends in CRC incidence among the Saudi population.</div></div><div><h3>Methods</h3><div>We used data from the Saudi Cancer Registry to examine CRC age-specific incidence rates (ASIR) and age-standardized incidence rates (ASR) between 1997 and 2017. Joinpoint regression analysis was used to determine the magnitude and direction of observed trends stratified by age, sex, and CRC stage at diagnosis. Trends were measured using the annual percentage change (APC) and the average annual percentage change (AAPC) in CRC incidence rates.</div></div><div><h3>Results</h3><div>In total, 19,463 new CRC cases were identified during the study period. Since 1997, ASR for CRC has steadily increased in men and women overall, irrespective of disease stages. The ASIR increased across all age groups and was more pronounced in older patients. Women aged 40–49 had a higher increase in incidence than men (AAPC= 5.3 % vs.4.7 %). Males aged 70–79 had an AAPC of 10.2 %, twice that of females (AAPC= 4.9 %). A consistent rise in ASIR was observed across all CRC stages and age groups in males and females. In recent years, males under 50 had a higher APC for distant CRC than females, while females aged 50–74 experienced a steeper increase in distant CRC than males.</div></div><div><h3>Conclusion</h3><div>We report a marked increase in the incidence of CRC over time in Saudi Arabia, affecting men and women across all age groups and disease stages at diagnosis. Our findings underscore the need to identify underlying risk factors and to develop and implement effective prevention policies and strategies, including screening programs to facilitate early detection and treatment.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"93 ","pages":"Article 102699"},"PeriodicalIF":2.4,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142633488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cancer in the Grand Libreville, Gabon (2013–2017) 加蓬大利伯维尔地区的癌症(2013-2017 年)。
IF 2.4 3区 医学 Q3 ONCOLOGY Pub Date : 2024-11-10 DOI: 10.1016/j.canep.2024.102695
Mahine Ivanga , D. Maxwell Parkin , Angela Filankembo Kava , Christian Nziengui Tirogo , Paul Nzamba Bissielou , Alex Kabena , Corinne Engohan Aloghe , Rose Revignet , Alexis Parente , Veronique Blanquet , Edgard Brice Ngoungou , Ismael Herve Koumakpayi , Ernest Belembaogo

Background

The burden of cancer is expected to nearly double in sub-Saharan Africa over the next 20 years. In Gabon, the primary population-based cancer registry to be established is located in the Grand Libreville. This study presents cancer incidence rates covering the first 5-year period of registration in this region.

Patients and methods

1,549 cancer cases were recorded among residents of the Grand Libreville between 2013 and 2017, 955 (61.6 %) women and 594 (38.3 %) males.

Results

The age standardized incidence rates (ASR) for all sites were 73.3 per 105 in females and 47.7 per 105 in males, rather similar from those observed in neighbouring countries of central Africa. Breast (ASR 19.0 per 105) and cervical cancers (ASR 16.3 per 105) accounted for half of female cancers. Prostate (ASR 12.0 per 105), liver (ASR 5.1 per 105) and colorectal cancers (ASR of 5.0 per 105) accounted for 41.1 % of male cancers.

Conclusion

Breast and prostate cancers ranked first in females and males, respectively, even if the incidences appear much lower in comparison with other regional cancer registries rates, implying they may be underestimated. Cancers of the digestive organs were markedly more frequent in men than women, especially for liver, colorectal (and anus) and the mouth and pharynx. The incidence rates of these latter cancers are relatively similar to those of other registries of the central African region. These results may be of importance for implementing more adapted strategies in the battle against cancer.
背景:在未来 20 年内,撒哈拉以南非洲地区的癌症负担预计将增加近一倍。在加蓬,以人口为基础的癌症登记处主要设在大利伯维尔。本研究介绍了该地区第一个5年登记期的癌症发病率。患者和方法:2013年至2017年期间,大利伯维尔居民共记录了1549例癌症病例,其中女性955例(61.6%),男性594例(38.3%):所有部位的年龄标准化发病率(ASR)分别为:女性73.3/105,男性47.7/105,与中部非洲邻国的发病率相当接近。乳腺癌(每 105 例中有 19.0 例)和宫颈癌(每 105 例中有 16.3 例)占女性癌症的一半。前列腺癌(每 105 人中 ASR 为 12.0)、肝癌(每 105 人中 ASR 为 5.1)和结肠直肠癌(每 105 人中 ASR 为 5.0)占男性癌症的 41.1%:结论:乳腺癌和前列腺癌分别在女性和男性中占首位,尽管与其他地区癌症登记率相比,这两种癌症的发病率似乎要低得多,这意味着它们可能被低估了。消化器官癌症在男性中的发病率明显高于女性,尤其是肝癌、结肠直肠癌(和肛门癌)以及口腔癌和咽喉癌。后几种癌症的发病率与中部非洲地区其他登记处的数据较为相似。这些结果对于在抗击癌症的斗争中实施更加适应的战略可能具有重要意义。
{"title":"Cancer in the Grand Libreville, Gabon (2013–2017)","authors":"Mahine Ivanga ,&nbsp;D. Maxwell Parkin ,&nbsp;Angela Filankembo Kava ,&nbsp;Christian Nziengui Tirogo ,&nbsp;Paul Nzamba Bissielou ,&nbsp;Alex Kabena ,&nbsp;Corinne Engohan Aloghe ,&nbsp;Rose Revignet ,&nbsp;Alexis Parente ,&nbsp;Veronique Blanquet ,&nbsp;Edgard Brice Ngoungou ,&nbsp;Ismael Herve Koumakpayi ,&nbsp;Ernest Belembaogo","doi":"10.1016/j.canep.2024.102695","DOIUrl":"10.1016/j.canep.2024.102695","url":null,"abstract":"<div><h3>Background</h3><div>The burden of cancer is expected to nearly double in sub-Saharan Africa over the next 20 years. In Gabon, the primary population-based cancer registry to be established is located in the Grand Libreville. This study presents cancer incidence rates covering the first 5-year period of registration in this region.</div></div><div><h3>Patients and methods</h3><div>1,549 cancer cases were recorded among residents of the Grand Libreville between 2013 and 2017, 955 (61.6 %) women and 594 (38.3 %) males.</div></div><div><h3>Results</h3><div>The age standardized incidence rates (ASR) for all sites were 73.3 per 10<sup>5</sup> in females and 47.7 per 10<sup>5</sup> in males, rather similar from those observed in neighbouring countries of central Africa. Breast (ASR 19.0 per 10<sup>5</sup>) and cervical cancers (ASR 16.3 per 10<sup>5</sup>) accounted for half of female cancers. Prostate (ASR 12.0 per 10<sup>5</sup>), liver (ASR 5.1 per 10<sup>5</sup>) and colorectal cancers (ASR of 5.0 per 10<sup>5</sup>) accounted for 41.1 % of male cancers.</div></div><div><h3>Conclusion</h3><div>Breast and prostate cancers ranked first in females and males, respectively, even if the incidences appear much lower in comparison with other regional cancer registries rates, implying they may be underestimated. Cancers of the digestive organs were markedly more frequent in men than women, especially for liver, colorectal (and anus) and the mouth and pharynx. The incidence rates of these latter cancers are relatively similar to those of other registries of the central African region. These results may be of importance for implementing more adapted strategies in the battle against cancer.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"93 ","pages":"Article 102695"},"PeriodicalIF":2.4,"publicationDate":"2024-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142633368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hospital as a site of death of cancer patients in Italy: A registry-based analysis and time trends 医院是意大利癌症患者的死亡地点:基于登记的分析和时间趋势。
IF 2.4 3区 医学 Q3 ONCOLOGY Pub Date : 2024-11-10 DOI: 10.1016/j.canep.2024.102702
Gianmauro Numico , Roberto Ippoliti , Andrea Antonuzzo , Lorenza Palmero , Paolo Bossi

Background

Place of death is relevant both for individuals and for the society. Home is universally considered the optimal place of death while dying in hospital may be a signal of inappropriate end-of-life care. We aimed at studying the place of death of patients with cancer in Italy in a five-year period.

Patients and methods

The death-certificate database published by the Italian National Institute of Statistics (ISTAT) was analysed, searching the place of death and the main disease related to death. Data from 2015 to 2019 were used, to exclude the influence of the COVID pandemic. Cancer, “cognitive impairment and Alzheimer’s disease” (CIAD) and “cardiovascular and cerebrovascular diseases” (CCD) were the examined diseases. The place of death was categorized as “acute care hospital”, “hospice” or “other long-term care (LTC) structures” and “home”. We implemented an ordinary linear regression model to verify whether there was a statistically significant variation across the selected time (i), and whether a substitution effect among sites of death could be hypothesized (ii).

Results

Data on 769,517 deaths were retrieved. In 2019 35.39 % patients with cancer died in hospital, 39.57 % died at home and 20.06 % died in hospice or in other LTC structures. In the examined period, death at home decreased by 3.09 % (95 % C.I. −3.18 - −2.99; p<0.01); death in hospice and long-term structures increased by 2.71 % (95 % C.I. 2.66 – 2.76; p<0.01); death in hospital increased by 0.3 % (95 % C.I. 0.23 – 0.36; p<0.01). For patients with CIAD, death in hospital increased by 0.98 % (95 % C.I. 0.80 – 1.17; p<001) and for patients with CCD decreased by 1.43 % (95 % I.C. −1.47 – −1.39; p<0.01). Death at home decreased in both diseases.

Conclusions

More than one-third of cancer patients die in acute care hospitals and this percentage is slightly increasing in the analysed period. Mortality at home decreased in all the examined diseases. Dying at home is being progressively less frequent, while hospitals continue to represent a frequent place of death.
背景:死亡地点与个人和社会都息息相关。人们普遍认为家是最佳的死亡地点,而在医院死亡则可能是临终关怀不当的信号。我们旨在研究五年内意大利癌症患者的死亡地点:我们分析了意大利国家统计局(ISTAT)发布的死亡证明数据库,搜索了死亡地点和与死亡相关的主要疾病。为排除COVID大流行的影响,使用了2015年至2019年的数据。癌症、"认知障碍和阿尔茨海默病"(CIAD)和 "心血管和脑血管疾病"(CCD)是研究的疾病。死亡地点分为 "急症护理医院"、"临终关怀 "或 "其他长期护理(LTC)机构 "和 "家庭"。我们采用普通线性回归模型来验证所选时间(i)之间是否存在统计学意义上的显著差异,以及是否可以假设死亡地点之间存在替代效应(ii):检索到 769 517 例死亡数据。2019年,35.39%的癌症患者死于医院,39.57%死于家中,20.06%死于临终关怀机构或其他长期护理机构。在调查期内,在家中死亡的比例下降了 3.09 %(95 % C.I. -3.18 - -2.99;p 结论:三分之一以上的癌症患者死于急症医院,在分析期内,这一比例略有上升。所有受检疾病的居家死亡率均有所下降。在家中死亡的情况正在逐渐减少,而医院仍然是一个常见的死亡地点。
{"title":"Hospital as a site of death of cancer patients in Italy: A registry-based analysis and time trends","authors":"Gianmauro Numico ,&nbsp;Roberto Ippoliti ,&nbsp;Andrea Antonuzzo ,&nbsp;Lorenza Palmero ,&nbsp;Paolo Bossi","doi":"10.1016/j.canep.2024.102702","DOIUrl":"10.1016/j.canep.2024.102702","url":null,"abstract":"<div><h3>Background</h3><div>Place of death is relevant both for individuals and for the society. Home is universally considered the optimal place of death while dying in hospital may be a signal of inappropriate end-of-life care. We aimed at studying the place of death of patients with cancer in Italy in a five-year period.</div></div><div><h3>Patients and methods</h3><div>The death-certificate database published by the Italian National Institute of Statistics (ISTAT) was analysed, searching the place of death and the main disease related to death. Data from 2015 to 2019 were used, to exclude the influence of the COVID pandemic. Cancer, “cognitive impairment and Alzheimer’s disease” (CIAD) and “cardiovascular and cerebrovascular diseases” (CCD) were the examined diseases. The place of death was categorized as “acute care hospital”, “hospice” or “other long-term care (LTC) structures” and “home”. We implemented an ordinary linear regression model to verify whether there was a statistically significant variation across the selected time (i), and whether a substitution effect among sites of death could be hypothesized (ii).</div></div><div><h3>Results</h3><div>Data on 769,517 deaths were retrieved. In 2019 35.39 % patients with cancer died in hospital, 39.57 % died at home and 20.06 % died in hospice or in other LTC structures. In the examined period, death at home decreased by 3.09 % (95 % C.I. −3.18 - −2.99; p&lt;0.01); death in hospice and long-term structures increased by 2.71 % (95 % C.I. 2.66 – 2.76; p&lt;0.01); death in hospital increased by 0.3 % (95 % C.I. 0.23 – 0.36; p&lt;0.01). For patients with CIAD, death in hospital increased by 0.98 % (95 % C.I. 0.80 – 1.17; p&lt;001) and for patients with CCD decreased by 1.43 % (95 % I.C. −1.47 – −1.39; p&lt;0.01). Death at home decreased in both diseases.</div></div><div><h3>Conclusions</h3><div>More than one-third of cancer patients die in acute care hospitals and this percentage is slightly increasing in the analysed period. Mortality at home decreased in all the examined diseases. Dying at home is being progressively less frequent, while hospitals continue to represent a frequent place of death.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"93 ","pages":"Article 102702"},"PeriodicalIF":2.4,"publicationDate":"2024-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142633480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prostate cancer incidence rates, trends, and treatment related to prostate-specific antigen screening recommendations in the United States 美国与前列腺特异性抗原筛查建议相关的前列腺癌发病率、趋势和治疗。
IF 2.4 3区 医学 Q3 ONCOLOGY Pub Date : 2024-11-09 DOI: 10.1016/j.canep.2024.102700
Ray M. Merrill

Background

Changes in US prostate-specific antigen (PSA) screening guidelines have impacted prostate cancer (PCa) incidence rates and trends. This study shows corresponding changes in PCa incidence rates and describes treatment patterns by tumor stage, age, and race/ethnicity.

Methods

Analyses were based on 777,152 cases diagnosed in 17 population-based tumor registries in the SEER Program of the US National Cancer Institute, 2007–2021. Rates were age adjusted and trends assessed using annual percent change and joinpoint regression.

Results

PCa age-adjusted incidence rates (per 100,000) fell from 165.8 in 2007 to 101 in 2014 (APC=-6.51, p<0.05) and then rose to 121.2 in 2021 (APC=1.87, p< 0.05). The significant fall and rise in rates appeared in ages 55–69 and ≥70, all racial/ethnic groups (except in Hispanics during 2014–2021), and in local/regional stage. PCa incidence rates by tumor stage, age, and race/ethnicity were presented and discussed. A few PCa cases were identified through autopsy or death certificate among the racial/ethnic groups (0.68 %-1.37 %). Unstaged cases identified through sources other than autopsy or death certificate significantly varied by race/ethnicity, ranging from 4.13 % for non-Hispanic (NH) Whites to 9.5 % for Hispanic (Chi-square p <.0001). In 2017–2021, surgery occurred in 33 % of cases (primarily in local/regional cases, inversely associated with age), radiation in 30 % of cases (increasing with age in local/regional stage cases and decreasing with age in distant stage cases), and chemotherapy in 2 % of cases (<1 % in local/regional stage cases and 9 %-38 % for age groups in distant stage cases). Several racial/ethnic differences in treatment exist, such as NH Blacks (vs. NH Whites) with local/regional disease were significantly less likely to receive surgery and more likely to receive radiation.

Conclusions

Understanding trends and patterns of PCa rates and treatment among patients by tumor stage, age, and race/ethnicity can guide public health planning in relation to screening and treatment.
背景:美国前列腺特异性抗原(PSA)筛查指南的变化影响了前列腺癌(PCa)的发病率和发病趋势。本研究显示了 PCa 发病率的相应变化,并按肿瘤分期、年龄和种族/人种描述了治疗模式:分析基于 2007-2021 年美国国家癌症研究所 SEER 计划中 17 个基于人群的肿瘤登记处诊断的 777,152 例病例。对发病率进行了年龄调整,并使用年度百分比变化和连接点回归对趋势进行了评估:结果:经年龄调整后的 PCa 发病率(每 10 万人)从 2007 年的 165.8 例降至 2014 年的 101 例(APC=-6.51,pConclusions):了解按肿瘤分期、年龄和种族/民族划分的 PCa 发病率和治疗趋势与模式,可为筛查和治疗方面的公共卫生规划提供指导。
{"title":"Prostate cancer incidence rates, trends, and treatment related to prostate-specific antigen screening recommendations in the United States","authors":"Ray M. Merrill","doi":"10.1016/j.canep.2024.102700","DOIUrl":"10.1016/j.canep.2024.102700","url":null,"abstract":"<div><h3>Background</h3><div>Changes in US prostate-specific antigen (PSA) screening guidelines have impacted prostate cancer (PCa) incidence rates and trends. This study shows corresponding changes in PCa incidence rates and describes treatment patterns by tumor stage, age, and race/ethnicity.</div></div><div><h3>Methods</h3><div>Analyses were based on 777,152 cases diagnosed in 17 population-based tumor registries in the SEER Program of the US National Cancer Institute, 2007–2021. Rates were age adjusted and trends assessed using annual percent change and joinpoint regression.</div></div><div><h3>Results</h3><div>PCa age-adjusted incidence rates (per 100,000) fell from 165.8 in 2007 to 101 in 2014 (APC=-6.51, p&lt;0.05) and then rose to 121.2 in 2021 (APC=1.87, p&lt; 0.05). The significant fall and rise in rates appeared in ages 55–69 and ≥70, all racial/ethnic groups (except in Hispanics during 2014–2021), and in local/regional stage. PCa incidence rates by tumor stage, age, and race/ethnicity were presented and discussed. A few PCa cases were identified through autopsy or death certificate among the racial/ethnic groups (0.68 %-1.37 %). Unstaged cases identified through sources other than autopsy or death certificate significantly varied by race/ethnicity, ranging from 4.13 % for non-Hispanic (NH) Whites to 9.5 % for Hispanic (Chi-square p &lt;.0001). In 2017–2021, surgery occurred in 33 % of cases (primarily in local/regional cases, inversely associated with age), radiation in 30 % of cases (increasing with age in local/regional stage cases and decreasing with age in distant stage cases), and chemotherapy in 2 % of cases (&lt;1 % in local/regional stage cases and 9 %-38 % for age groups in distant stage cases). Several racial/ethnic differences in treatment exist, such as NH Blacks (vs. NH Whites) with local/regional disease were significantly less likely to receive surgery and more likely to receive radiation.</div></div><div><h3>Conclusions</h3><div>Understanding trends and patterns of PCa rates and treatment among patients by tumor stage, age, and race/ethnicity can guide public health planning in relation to screening and treatment.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"93 ","pages":"Article 102700"},"PeriodicalIF":2.4,"publicationDate":"2024-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142633485","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Life years lost by childhood cancer treatment and health related late effects among childhood cancer survivors 儿童癌症治疗损失的寿命年数以及儿童癌症幸存者中与健康相关的晚期影响。
IF 2.4 3区 医学 Q3 ONCOLOGY Pub Date : 2024-11-07 DOI: 10.1016/j.canep.2024.102692
Thibaud Charrier , Nadia Haddy , Brice Fresneau , Boris Schwartz , Neige Journy , Charlotte Demoor-Goldschmidt , Ibrahima Diallo , Isabelle Aerts , François Doz , Vincent Souchard , Giao Vu-Bezin , Anne Laprie , Sarah Lemler , Véronique Letort , Carole Rubino , Kaniav Kamary , Naïla Myriam Aba , Claire Ducos , Médéa Locquet , Florent de Vathaire , Aurélien Latouche

Background

Identifying risk factors contributing the most to mortality of childhood cancer survivors is essential to guide harm reduction efforts in childhood cancer treatments, and long-term follow-up of childhood cancer survivors.

Methods

We assessed Life Years Lost from childhood cancer treatments and their health-related late effects among the French Childhood Cancer Survivors Study, a cohort of 7670 5-year childhood cancer survivors. Using a landmark strategy, we also assessed time-varying effects of risk factors, and how the multi-morbidity affects life years lost.

Results

We found subsequent malignant neoplasm (9.0 years [95 %CI: 4.3–13.7]), severe cardiac disease (8.0 years [95 %CI: 1.2–14.9]), and the use of radiotherapy (6.0 years [95 %CI: 4.7–7.3]) to be the highest contributors to Life Years Lost among childhood cancer survivors. We found no interaction impact on life years lost between health related late effects considered.

Conclusions

Those findings suggest that radiotherapy is the root cause of early mortality among childhood cancer survivors. Moreover patients experiencing a subsequent malignant neoplasm or a cardiac disease should be monitored closely after the event, as comorbidity is common and causes premature deaths.
背景:确定导致儿童癌症幸存者死亡的最主要风险因素对于指导儿童癌症治疗中的减害工作以及儿童癌症幸存者的长期随访至关重要:我们评估了 "法国儿童癌症幸存者研究"(French Childhood Cancer Survivors Study)中儿童癌症治疗损失的生命年数及其对健康的后期影响。我们还采用地标策略评估了风险因素的时变效应,以及多种疾病如何影响寿命损失:我们发现,恶性肿瘤(9.0 年 [95 %CI:4.3-13.7])、严重心脏病(8.0 年 [95 %CI:1.2-14.9])和放疗(6.0 年 [95 %CI:4.7-7.3])是导致儿童癌症幸存者寿命损失最多的因素。我们发现,与健康相关的晚期效应对寿命损失年数没有交互影响:这些研究结果表明,放疗是导致儿童癌症幸存者早期死亡的根本原因。此外,由于合并症很常见并会导致过早死亡,因此应密切监测继发恶性肿瘤或心脏病的患者。
{"title":"Life years lost by childhood cancer treatment and health related late effects among childhood cancer survivors","authors":"Thibaud Charrier ,&nbsp;Nadia Haddy ,&nbsp;Brice Fresneau ,&nbsp;Boris Schwartz ,&nbsp;Neige Journy ,&nbsp;Charlotte Demoor-Goldschmidt ,&nbsp;Ibrahima Diallo ,&nbsp;Isabelle Aerts ,&nbsp;François Doz ,&nbsp;Vincent Souchard ,&nbsp;Giao Vu-Bezin ,&nbsp;Anne Laprie ,&nbsp;Sarah Lemler ,&nbsp;Véronique Letort ,&nbsp;Carole Rubino ,&nbsp;Kaniav Kamary ,&nbsp;Naïla Myriam Aba ,&nbsp;Claire Ducos ,&nbsp;Médéa Locquet ,&nbsp;Florent de Vathaire ,&nbsp;Aurélien Latouche","doi":"10.1016/j.canep.2024.102692","DOIUrl":"10.1016/j.canep.2024.102692","url":null,"abstract":"<div><h3>Background</h3><div>Identifying risk factors contributing the most to mortality of childhood cancer survivors is essential to guide harm reduction efforts in childhood cancer treatments, and long-term follow-up of childhood cancer survivors.</div></div><div><h3>Methods</h3><div>We assessed Life Years Lost from childhood cancer treatments and their health-related late effects among the French Childhood Cancer Survivors Study, a cohort of 7670 5-year childhood cancer survivors. Using a landmark strategy, we also assessed time-varying effects of risk factors, and how the multi-morbidity affects life years lost.</div></div><div><h3>Results</h3><div>We found subsequent malignant neoplasm (9.0 years [95 %CI: 4.3–13.7]), severe cardiac disease (8.0 years [95 %CI: 1.2–14.9]), and the use of radiotherapy (6.0 years [95 %CI: 4.7–7.3]) to be the highest contributors to Life Years Lost among childhood cancer survivors. We found no interaction impact on life years lost between health related late effects considered.</div></div><div><h3>Conclusions</h3><div>Those findings suggest that radiotherapy is the root cause of early mortality among childhood cancer survivors. Moreover patients experiencing a subsequent malignant neoplasm or a cardiac disease should be monitored closely after the event, as comorbidity is common and causes premature deaths.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"93 ","pages":"Article 102692"},"PeriodicalIF":2.4,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142606561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The challenge of ovarian cancer care in the oldest old. 高龄老人卵巢癌护理面临的挑战。
IF 2.4 3区 医学 Q3 ONCOLOGY Pub Date : 2024-11-05 DOI: 10.1016/j.canep.2024.102697
Jérémy Barben, Angéline Galvin, Ariane Mamguem Kamga, Nicolas Bertrand, Julie Niogret, Julie Tisserand, Valérie Quipourt, Leila Bengrine-Lefevre, Tienhan Sandrine Dabakuyo-Yonli

Introduction: Ovarian cancer (OC) is the eighth most common cancer in women, with a poor prognosis, particularly in older women. The aim of this study was to describe an octogenarian population with OC and to examine the differences in net survival (NS) according to age.

Material and methods: In this retrospective observational population-based study from a gynecological cancer registry, patients aged > 18 years with an identified epithelial ovarian cancer stage IA to IVB diagnosed between 1998 and 2018 were included. Patients with non-available FIGO stage were excluded. Patients were stratified into three age groups: <70, 70-79 and ≥80 years, then by OC stage (FIGO I-II, IIIA-IIIB, IIIC-IV). Sociodemographic and cancer-related variables were compared using univariate test (Khi²). The 5-year NS was calculated using the Pohar-Perme method.

Results: Among the 721 patients included: 462 (64.1 %) were younger than 70 years, 176 (24.4 %) were aged between 70 and 79 years, and 83 (11.85 %) were aged 80 years or older. Patients ≥80 years had a trend for lower rate of serous carcinoma than the other age subgroups. As age increased, patients were less likely to undergo surgery and chemotherapy. While 73 % of women <70 years received a combination of surgery and chemotherapy, the rate was 62 % among women 70-79 years and 27 % among women ≥80 years (p<.0001). When focusing on FIGO IIIC-IV stages, the 5-year NS rate for women <70 years was 45.1 % (95 % CI 39.1-52.0). For women 70-79 years, it was 25.9 % (95 % CI 18.6-36.1), and for those ≥80 years, it was 19.5 % (95 % CI 10.0-38.0) (p<.005).

Discussion: The oldest patients had less optimal treatment and a lower NS compared to patients in their seventies or younger. Frailty should be carefully assessed to optimize care in the oldest patients with OC.

简介卵巢癌(OC)是妇女第八大常见癌症,预后较差,尤其是老年妇女。本研究旨在描述八十岁以上卵巢癌患者的情况,并研究净生存率(NS)在不同年龄段的差异:在这项基于人群的回顾性观察研究中,纳入了 1998 年至 2018 年间确诊的上皮性卵巢癌 IA 期至 IVB 期、年龄大于 18 岁的妇科癌症登记患者。未提供FIGO分期的患者被排除在外。患者分为三个年龄组:结果:在纳入的 721 名患者中:462人(64.1%)小于70岁,176人(24.4%)年龄在70-79岁之间,83人(11.85%)年龄在80岁或以上。与其他年龄亚组相比,≥80 岁患者的浆液性癌发生率呈下降趋势。随着年龄的增长,患者接受手术和化疗的可能性降低。73%的女性进行了讨论:与 70 多岁或更年轻的患者相比,高龄患者的最佳治疗效果较差,NS 也较低。应仔细评估体弱情况,以优化对高龄 OC 患者的护理。
{"title":"The challenge of ovarian cancer care in the oldest old.","authors":"Jérémy Barben, Angéline Galvin, Ariane Mamguem Kamga, Nicolas Bertrand, Julie Niogret, Julie Tisserand, Valérie Quipourt, Leila Bengrine-Lefevre, Tienhan Sandrine Dabakuyo-Yonli","doi":"10.1016/j.canep.2024.102697","DOIUrl":"https://doi.org/10.1016/j.canep.2024.102697","url":null,"abstract":"<p><strong>Introduction: </strong>Ovarian cancer (OC) is the eighth most common cancer in women, with a poor prognosis, particularly in older women. The aim of this study was to describe an octogenarian population with OC and to examine the differences in net survival (NS) according to age.</p><p><strong>Material and methods: </strong>In this retrospective observational population-based study from a gynecological cancer registry, patients aged > 18 years with an identified epithelial ovarian cancer stage IA to IVB diagnosed between 1998 and 2018 were included. Patients with non-available FIGO stage were excluded. Patients were stratified into three age groups: <70, 70-79 and ≥80 years, then by OC stage (FIGO I-II, IIIA-IIIB, IIIC-IV). Sociodemographic and cancer-related variables were compared using univariate test (Khi²). The 5-year NS was calculated using the Pohar-Perme method.</p><p><strong>Results: </strong>Among the 721 patients included: 462 (64.1 %) were younger than 70 years, 176 (24.4 %) were aged between 70 and 79 years, and 83 (11.85 %) were aged 80 years or older. Patients ≥80 years had a trend for lower rate of serous carcinoma than the other age subgroups. As age increased, patients were less likely to undergo surgery and chemotherapy. While 73 % of women <70 years received a combination of surgery and chemotherapy, the rate was 62 % among women 70-79 years and 27 % among women ≥80 years (p<.0001). When focusing on FIGO IIIC-IV stages, the 5-year NS rate for women <70 years was 45.1 % (95 % CI 39.1-52.0). For women 70-79 years, it was 25.9 % (95 % CI 18.6-36.1), and for those ≥80 years, it was 19.5 % (95 % CI 10.0-38.0) (p<.005).</p><p><strong>Discussion: </strong>The oldest patients had less optimal treatment and a lower NS compared to patients in their seventies or younger. Frailty should be carefully assessed to optimize care in the oldest patients with OC.</p>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":" ","pages":"102697"},"PeriodicalIF":2.4,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142592331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
New South Wales data linkage study reveals a shift in HCC mortality risk: Time for broader strategies 新南威尔士州数据关联研究揭示了 HCC 死亡风险的变化:制定更广泛战略的时机已到
IF 2.4 3区 医学 Q3 ONCOLOGY Pub Date : 2024-10-31 DOI: 10.1016/j.canep.2024.102690
Salim Maher , Alamgir Kabir , Jason Behary , Damian P. Conway , Anna C. Akon , Margo Barr , Amany Zekry

Background

This study aims to examine the impact of sociodemographic and clinical factors on hepatocellular carcinoma (HCC) mortality in New South Wales (NSW), Australia.

Methods

We conducted a 15-year retrospective study (2001–2015) using data linkage of health records and cancer registry databases, to identify all HCC cases and analyse HCC-related and all-cause mortality rates. Location-based socioeconomic status (SES) was determined using the Socioeconomic Indexes for Areas (SEIFA). Multivariable Cox regression analysis was used to determine the effect of key variables on mortality.

Results

5564 cases of HCC were diagnosed during the study period. A study cohort of 5454 cases was analysed after excluding cases with key missing data. More than half of the chronic liver disease cases were due to non-viral causes. During the study period, 4033 deaths occurred, of which 2862 were HCC-related. The median survival time for HCC-related deaths was 547 days, and the 5-year survival rate was 31.3 %. Higher HCC-related mortality rates were observed in SEIFA quintiles 2, 3 and 4, when compared to 5 (where SEIFA 1 is most disadvantaged, and SEIFA 5 is most advantaged). Furthermore, significantly increased HCC-related mortality was observed for those aged ≥65, male gender, Australian-born, hospitalisation due to complications of alcohol use, having metastatic HCC at diagnosis, and not receiving surgery for HCC.

Conclusions

There is higher prevalence of non-viral-related HCC than viral-related HCC in NSW, Australia, where HCC-related mortality risk is greatest among those Australian-born and lower to higher SES, when compared to highest SES. Identifying factors contributing to these emerging disparities is crucial for developing effective prevention programs and allocating research and health resources.
背景本研究旨在探讨澳大利亚新南威尔士州(NSW)的社会人口和临床因素对肝细胞癌(HCC)死亡率的影响。方法我们利用健康记录和癌症登记数据库的数据链接开展了一项为期 15 年(2001-2015 年)的回顾性研究,以确定所有 HCC 病例并分析 HCC 相关死亡率和全因死亡率。使用地区社会经济指数(SEIFA)确定了基于地点的社会经济地位(SES)。采用多变量 Cox 回归分析确定主要变量对死亡率的影响。在排除关键数据缺失的病例后,对 5454 个病例的研究队列进行了分析。半数以上的慢性肝病病例由非病毒引起。在研究期间,共有4033人死亡,其中2862人与HCC有关。HCC相关死亡病例的中位生存时间为547天,5年生存率为31.3%。与 SEIFA 五分位数 5 相比,SEIFA 五分位数 2、3 和 4 的 HCC 相关死亡率更高(SEIFA 五分位数 1 最不利,SEIFA 五分位数 5 最有利)。此外,年龄≥65 岁、男性、澳大利亚出生、因酗酒并发症住院、诊断时为转移性 HCC 以及未接受 HCC 手术治疗的人群的 HCC 相关死亡率也明显增加。结论在澳大利亚新南威尔士州,非病毒相关 HCC 的发病率高于病毒相关 HCC,与最高社会经济地位相比,澳大利亚出生和较低至较高社会经济地位人群的 HCC 相关死亡风险最大。找出导致这些新出现的差异的因素对于制定有效的预防计划以及分配研究和卫生资源至关重要。
{"title":"New South Wales data linkage study reveals a shift in HCC mortality risk: Time for broader strategies","authors":"Salim Maher ,&nbsp;Alamgir Kabir ,&nbsp;Jason Behary ,&nbsp;Damian P. Conway ,&nbsp;Anna C. Akon ,&nbsp;Margo Barr ,&nbsp;Amany Zekry","doi":"10.1016/j.canep.2024.102690","DOIUrl":"10.1016/j.canep.2024.102690","url":null,"abstract":"<div><h3>Background</h3><div>This study aims to examine the impact of sociodemographic and clinical factors on hepatocellular carcinoma (HCC) mortality in New South Wales (NSW), Australia.</div></div><div><h3>Methods</h3><div>We conducted a 15-year retrospective study (2001–2015) using data linkage of health records and cancer registry databases, to identify all HCC cases and analyse HCC-related and all-cause mortality rates. Location-based socioeconomic status (SES) was determined using the Socioeconomic Indexes for Areas (SEIFA). Multivariable Cox regression analysis was used to determine the effect of key variables on mortality.</div></div><div><h3>Results</h3><div>5564 cases of HCC were diagnosed during the study period. A study cohort of 5454 cases was analysed after excluding cases with key missing data. More than half of the chronic liver disease cases were due to non-viral causes. During the study period, 4033 deaths occurred, of which 2862 were HCC-related. The median survival time for HCC-related deaths was 547 days, and the 5-year survival rate was 31.3 %. Higher HCC-related mortality rates were observed in SEIFA quintiles 2, 3 and 4, when compared to 5 (where SEIFA 1 is most disadvantaged, and SEIFA 5 is most advantaged). Furthermore, significantly increased HCC-related mortality was observed for those aged ≥65, male gender, Australian-born, hospitalisation due to complications of alcohol use, having metastatic HCC at diagnosis, and not receiving surgery for HCC.</div></div><div><h3>Conclusions</h3><div>There is higher prevalence of non-viral-related HCC than viral-related HCC in NSW, Australia, where HCC-related mortality risk is greatest among those Australian-born and lower to higher SES, when compared to highest SES. Identifying factors contributing to these emerging disparities is crucial for developing effective prevention programs and allocating research and health resources.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"93 ","pages":"Article 102690"},"PeriodicalIF":2.4,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142560739","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Epidemiological and clinical characteristics of hepatocellular carcinoma in Xiamen 厦门肝细胞癌的流行病学和临床特征
IF 2.4 3区 医学 Q3 ONCOLOGY Pub Date : 2024-10-31 DOI: 10.1016/j.canep.2024.102691
Zhenzhen Zhang , Meixia Wang , Yanfang Wu , Guobin Chen , Boheng Zhang

Objective

To investigate the epidemiological characteristics of hepatocellular carcinoma in Xiamen and offer recommendations for its control and prevention. Methods: Data obtained from liver cancer screening in 2016–2018 and 2019–2020 in patients with hepatocellular carcinoma in Xiamen were collected using Xiamen Healthcare Big Data Platform. Epidemiological characteristics were analyzed descriptively by different years. Results: From 2016–2020, there were 3740 patients with hepatocellular carcinoma in Xiamen. In the patients, the percentage of males was higher than that of females (83.13 % vs 16.87 %). From 2019–2020, there was an increase in the detection rates for disorders including hepatitis B, hypertension, diabetes, fatty liver and cirrhosis of the liver, and there was a decrease in the prevalence of hepatitis C. There was an increase in the values of all hematological indicators of infection in patients with liver cancer in 2019–2020 compared with the previous three years. From 2016–2020, there was a year-on-year increase in the prevalence of liver cancer and fatty liver. From 2018–2020, there was an increasing trend in the prevalence of liver cancer in overweight patients in the population with fatty liver. Conclusion: In 2019–2020, there was an increase in the prevalence of chronic diseases in patients with hepatocellular carcinoma. Comprehensive liver cancer screening provides an important guide for the prevention, early diagnosis and treatment of liver cancer and for clinicians to assess patients’ condition.
目的 调查厦门地区肝细胞癌的流行病学特征,并为其控制和预防提供建议。方法:利用厦门市健康医疗大数据平台,收集2016-2018年和2019-2020年厦门市肝癌患者的肝癌筛查数据。按不同年份对流行病学特征进行描述性分析。结果显示2016-2020年,厦门市共有3740名肝细胞癌患者。患者中,男性比例高于女性(83.13% vs 16.87%)。2019-2020年,乙肝、高血压、糖尿病、脂肪肝、肝硬化等疾病检出率有所上升,丙肝患病率有所下降,2019-2020年肝癌患者各项血液学感染指标值较前三年有所上升。2016-2020 年,肝癌和脂肪肝的患病率逐年上升。2018-2020年,脂肪肝人群中超重患者的肝癌患病率呈上升趋势。结论2019-2020年,肝癌患者中慢性病患病率呈上升趋势。肝癌综合筛查为肝癌的预防、早期诊断和治疗以及临床医生评估患者病情提供了重要指导。
{"title":"Epidemiological and clinical characteristics of hepatocellular carcinoma in Xiamen","authors":"Zhenzhen Zhang ,&nbsp;Meixia Wang ,&nbsp;Yanfang Wu ,&nbsp;Guobin Chen ,&nbsp;Boheng Zhang","doi":"10.1016/j.canep.2024.102691","DOIUrl":"10.1016/j.canep.2024.102691","url":null,"abstract":"<div><h3>Objective</h3><div>To investigate the epidemiological characteristics of hepatocellular carcinoma in Xiamen and offer recommendations for its control and prevention. Methods: Data obtained from liver cancer screening in 2016–2018 and 2019–2020 in patients with hepatocellular carcinoma in Xiamen were collected using Xiamen Healthcare Big Data Platform. Epidemiological characteristics were analyzed descriptively by different years. Results: From 2016–2020, there were 3740 patients with hepatocellular carcinoma in Xiamen. In the patients, the percentage of males was higher than that of females (83.13 % vs 16.87 %). From 2019–2020, there was an increase in the detection rates for disorders including hepatitis B, hypertension, diabetes, fatty liver and cirrhosis of the liver, and there was a decrease in the prevalence of hepatitis C. There was an increase in the values of all hematological indicators of infection in patients with liver cancer in 2019–2020 compared with the previous three years. From 2016–2020, there was a year-on-year increase in the prevalence of liver cancer and fatty liver. From 2018–2020, there was an increasing trend in the prevalence of liver cancer in overweight patients in the population with fatty liver. Conclusion: In 2019–2020, there was an increase in the prevalence of chronic diseases in patients with hepatocellular carcinoma. Comprehensive liver cancer screening provides an important guide for the prevention, early diagnosis and treatment of liver cancer and for clinicians to assess patients’ condition.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"93 ","pages":"Article 102691"},"PeriodicalIF":2.4,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142560741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A competing-risk nomogram for predicting gastric cancer-specific survival in patients over 70 years: A SEER-based study 用于预测 70 岁以上患者胃癌特异性生存期的竞争风险提名图:基于 SEER 的研究
IF 2.4 3区 医学 Q3 ONCOLOGY Pub Date : 2024-10-31 DOI: 10.1016/j.canep.2024.102696
Maorun Zhang , Xuliang Yang , Jinyan Jia , Qi Zhang , Heyuan Niu , Tao Yu , Gang Liu

Background

Cancer-specific survival in older patients with gastric cancer is competitively affected by death from other causes. This study aimed to investigate cancer-specific survival and associated risk factors by competing-risk analysis in older patients with gastric cancer.

Methods

The data of this study are from the SEER database, using univariable and multivariable analysis of competitive risk model to weaken the impact of competitive events, explore the risk factors of cancer-specific survival, and developed a nomogram model. Then, the performance of the model is verified by C-index, ROC curve, calibration curve and DCA, and the new model is compared with the traditional TNM stage by NRI and IDI.

Results

Our study encompassed a total of 8183 patients, with 5731 in the training cohort and 2452 in the validation cohort. Univariable and multivariable analysis showed that age, years of diagnosis, race, site, SEER stage, TNM stage, surgery, radiation or chemotherapy, LNE, tumor grade and size are independent risk factors for cancer-specific survival in older patients with gastric cancer. Based on the risk factors, we developed a diagram model to predict cancer-specific survival. C-index, ROC curve, calibration curve and DCA also show good results. We compared the new model with the traditional TNM stage model, and the NRI and IDI showed the new model has been significantly improved.

Conclusion

This study developed a nomogram to predict the cancer-specific survival of older patients with gastric cancer, which can accurately predict the prognosis and contribute to clinical treatment decision-making.
背景老年胃癌患者的癌症特异性生存率受到其他原因导致的死亡的竞争性影响。方法本研究的数据来自 SEER 数据库,采用单变量和多变量分析竞争风险模型削弱竞争事件的影响,探索癌症特异性生存的风险因素,并建立了一个提名图模型。然后,通过 C 指数、ROC 曲线、校准曲线和 DCA 验证了该模型的性能,并通过 NRI 和 IDI 将新模型与传统 TNM 分期进行了比较。单变量和多变量分析表明,年龄、诊断年限、种族、部位、SEER分期、TNM分期、手术、放疗或化疗、LNE、肿瘤分级和大小是老年胃癌患者癌症特异性生存的独立危险因素。根据这些风险因素,我们建立了一个预测癌症特异性生存率的图表模型。C指数、ROC曲线、校准曲线和DCA也显示出良好的效果。我们将新模型与传统的 TNM 分期模型进行了比较,结果表明新模型的 NRI 和 IDI 有了明显改善。
{"title":"A competing-risk nomogram for predicting gastric cancer-specific survival in patients over 70 years: A SEER-based study","authors":"Maorun Zhang ,&nbsp;Xuliang Yang ,&nbsp;Jinyan Jia ,&nbsp;Qi Zhang ,&nbsp;Heyuan Niu ,&nbsp;Tao Yu ,&nbsp;Gang Liu","doi":"10.1016/j.canep.2024.102696","DOIUrl":"10.1016/j.canep.2024.102696","url":null,"abstract":"<div><h3>Background</h3><div>Cancer-specific survival in older patients with gastric cancer is competitively affected by death from other causes. This study aimed to investigate cancer-specific survival and associated risk factors by competing-risk analysis in older patients with gastric cancer.</div></div><div><h3>Methods</h3><div>The data of this study are from the SEER database, using univariable and multivariable analysis of competitive risk model to weaken the impact of competitive events, explore the risk factors of cancer-specific survival, and developed a nomogram model. Then, the performance of the model is verified by C-index, ROC curve, calibration curve and DCA, and the new model is compared with the traditional TNM stage by NRI and IDI.</div></div><div><h3>Results</h3><div>Our study encompassed a total of 8183 patients, with 5731 in the training cohort and 2452 in the validation cohort. Univariable and multivariable analysis showed that age, years of diagnosis, race, site, SEER stage, TNM stage, surgery, radiation or chemotherapy, LNE, tumor grade and size are independent risk factors for cancer-specific survival in older patients with gastric cancer. Based on the risk factors, we developed a diagram model to predict cancer-specific survival. C-index, ROC curve, calibration curve and DCA also show good results. We compared the new model with the traditional TNM stage model, and the NRI and IDI showed the new model has been significantly improved.</div></div><div><h3>Conclusion</h3><div>This study developed a nomogram to predict the cancer-specific survival of older patients with gastric cancer, which can accurately predict the prognosis and contribute to clinical treatment decision-making.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"93 ","pages":"Article 102696"},"PeriodicalIF":2.4,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142560740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comment on “Metformin's role in lowering colorectal cancer risk among individuals with diabetes from the Southern Community Cohort Study” 就 "二甲双胍在降低南方社区队列研究中糖尿病患者患结直肠癌风险方面的作用 "发表评论。
IF 2.4 3区 医学 Q3 ONCOLOGY Pub Date : 2024-10-30 DOI: 10.1016/j.canep.2024.102694
Shih-Wei Lai, Kuan-Fu Liao
{"title":"Comment on “Metformin's role in lowering colorectal cancer risk among individuals with diabetes from the Southern Community Cohort Study”","authors":"Shih-Wei Lai,&nbsp;Kuan-Fu Liao","doi":"10.1016/j.canep.2024.102694","DOIUrl":"10.1016/j.canep.2024.102694","url":null,"abstract":"","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"93 ","pages":"Article 102694"},"PeriodicalIF":2.4,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142549213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Cancer Epidemiology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1